Full Press Release Details
InMed to Present at H.C. Wainwright 25th Annual
Global Investment Conference
Vancouver, BC - September 7, 2023 -
InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the pharmaceutical
research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announce that InMed's
Chief Executive Officer, Eric A. Adam's will present a company overview at the H.C. Wainwright
25th Annual Global Investment Conference which takes place September 11-13, 2023 in New York City.
The on-demand presentation by InMed's Chief
Executive Officer, Eric A. Adams, will be made available on September 11, 2023, at 7:00 AM ET. The presentation will be available via
webcast archived in the News & Events section of InMed's Investor Relations website for a period of 90 days.
management team will be available for onsite and virtual one-on-one meetings with registered investors during the conference.
InMed Pharmaceuticals is a global leader in the
research, development, manufacturing and commercialization of rare cannabinoids, including clinical and preclinical programs targeting
the treatment of diseases with high unmet medical needs. We also have significant know-how in developing proprietary manufacturing approaches
to produce cannabinoids for various market sectors. For more information, visit www.inmedpharma.com and https://www.baymedica.com/.
Vice President, Investor Relations
and Corporate Communications
Cautionary Note Regarding Forward-Looking Information:
This news release contains "forward-looking
information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning
of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to
a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.
Forward-looking information in this news release includes statements about: InMed's participation in future conferences; being a
global leader in the research, development, manufacturing and commercialization of rare cannabinoids, including clinical and preclinical
programs targeting the treatment of diseases with high unmet medical needs; having significant know-how in developing proprietary manufacturing
approaches to produce cannabinoids for various market sectors.
Additionally, there are known and unknown risk
factors which could cause InMed's actual results, performance or achievements to be materially different from any future results, performance
or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties
facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K and other filings with the Securities
and Exchange Commission on www.sec.gov.
All forward-looking information herein is qualified
in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information
or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results,
events or developments, except as required by law.